ProtoKinetix Company Information
Supported by some of the world’s top scientists and backed by more than a decade of international laboratory testing, ProtoKinetix has developed a substantial body of trade secrets relating to the development, use and manufacture of AAGP®, our proprietary anti-aging glycopeptide.
With incredible abilities to protect cells from inflammation, AAGP® has the potential to transform future health therapies for ophthalmology, dermatology, transplants and biomanufacturing. Review our company information below to learn more.
ProtoKinetix is a biotech stock to watch
We are a debt-free company on solid financial footing. Review our recent SEC filings to see our current financial information.
Committed to providing hope for more patients.
Accountable to our investors and shareholders.
Why? We are steadfast in our pursuit of prudent and responsible business practices because our progress depends on continued investor support.
Dedicated to human biology-based research.
The leaders at ProtoKinetix have a clear vision for the future of the company and for the future of regenerative medicine. Learn more about their backgrounds.
See how our company is leading the way in cell survival solutions that will revolutionize the future of ophthalmology, dermatology, transplants and biomanufacturing.
Contact a member of our team to request more information.